Bellevue Life Sciences Acquisition Corp.
Completed 2025-02-14- CIK 1840425
- BLAC
- Now OSRH
- IPO 2023-02-13
- $1.8M trust
- 224 filings
Successfully merged with OSR Holdings Co., Ltd. • Now trading as OSRH
- IPO Size
- $69M
- raised at the IPO
- Trust
- $1.8M
- as of 2024-12-31
- Current Status
- Completed
- from its latest filing
- IPO Year
- 2023
- year it listed
Filings, by quarter
224 filings over 24 quarters; violet bars carry a milestone
- 21 Q1: 1 filing
- 21 Q2: 1 filing
- 21 Q3: 0 filings
- 21 Q4: 4 filings
- 22 Q1: 0 filings
- 22 Q2: 8 filings
- 22 Q3: 0 filings
- 22 Q4: 6 filings
- 23 Q1: 37 filings
- 23 Q2: 4 filings
- 23 Q3: 3 filings
- 23 Q4: 13 filings
- 24 Q1: 9 filings
- 24 Q2: 19 filings
- 24 Q3: 10 filings
- 24 Q4: 21 filings
- 25 Q1: 30 filings
- 25 Q2: 13 filings
- 25 Q3: 10 filings
- 25 Q4: 4 filings
- 26 Q1: 5 filings
- 26 Q2: 15 filings
- 26 Q3: 10 filings
- 26 Q4: 1 filing
- S-1 filed 21 Q1
- IPO 23 Q1
- Definitive agreement 23 Q4
- Completed 25 Q1
SPAC Overview
Where it stands on the road from S-1 to merger
Timeline Progress
About
Bellevue Life Sciences Acquisition Corp. is a blank-check company seeking an initial business combination, intending to focus on healthcare and, specifically, biotechnology. It expects to leverage healthcare investment and Korean capital-markets expertise to identify target businesses, particularly firms based in Korea.
Investment Focus
Healthcare, Biopharmaceuticals
Geographic Focus
South Korea
Key Information
As the filings state it
- IPO Date
- 2023-02-13
- Total Redemptions
- $72.2M
- PIPE
- $20M
- Jurisdiction of Incorporation
- Delaware
- SIC
- 6770
- Completion Date
- 2025-02-14
- Merger Target
- OSR Holdings Co., Ltd.
- SPAC Ticker
- BLAC
- Merged Ticker
- OSRH
Stock Performance
OSRHTrading symbol, and its price at each step since the first trade
| Point | Date | Price | Move |
|---|---|---|---|
| First Trade | 2023-03-21 | $10.10 | |
| At Merger | 2025-02-18 | $3.11 | -69% |
| 6 Months Post-Merger | 2025-08-18 | $0.56 | -82% |
| 1 Year Post-Merger | 2026-02-17 | $0.46 | -85% |
| Current Price | 2026-10-09 | $0.19 | -98% |
SPAC Team
The banks on its IPO, and the team as the filings describe it
Underwriters
Extended Team Information
Led by Kuk Hyoun Hwang, David J. Yoo and Jun Chul Whang, with experience in healthcare investing, investment banking, M&A and investment management; director nominees add biotechnology, life sciences, finance and business-development experience.